## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.2% below STRENGTH zone (3.0-6.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($120.12)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. FDA Warning For Abbott Glucose Sensors After 700 Injuries, 7 Deaths - Abbott Laboratories (NYSE:ABT)**
- Source: Benzinga | 20251205T170722 | Neutral | Relevance: 99%
- The FDA has issued a safety alert for select Abbott Laboratories' FreeStyle Libre 3 glucose sensors after reports of 736 serious injuries and seven deaths linked to inaccurate low glucose readings. These inaccuracies could lead to dangerous treatment decisions for individuals with diabetes. Abbott has advised patients to check their sensors and discard affected devices, while other FreeStyle Libre products remain safe.

**2. Guggenheim Capital LLC Buys 11,794 Shares of Abbott Laboratories $ABT**
- Source: MarketBeat | 20251205T122331 | Bullish | Relevance: 99%
-  Guggenheim Capital LLC increased its stake in Abbott Laboratories (NYSE:ABT) by 13.5% in the second quarter, purchasing an additional 11,794 shares. Several other institutional investors also adjusted their positions in the company, with some significantly raising their holdings. Analyst ratings for Abbott Laboratories are predominantly positive, with a "Moderate Buy" consensus and an average target price of $147.00.

**3. The Zacks Analyst Blog Highlights HSBC, Abbott, Shell and Oak Valley**
- Source: Yahoo Finance | 20251205T061200 | Bullish | Relevance: 99%
-  This Zacks Analyst Blog highlights recent research reports on major stocks including HSBC Holdings plc, Abbott Laboratories, Shell plc, and micro-cap Oak Valley Bancorp. The report details company performance, growth drivers, challenges, and future outlooks for these entities. It also mentions "Ahead of Wall Street" for pre-market insights and offers free access to Zacks' stock-picking strategies.

**4. Molecular Cytogenetics Market Intelligence Report (2020-2030) Featuring Key Players Danaher, MetaSystems, Agilent Technologies, Abbott Labs, Bio-Rad Labs and More - ResearchAndMarkets.com**
- Source: The AI Journal | 20251204T170427 | Somewhat-Bullish | Relevance: 98%
-  The global Molecular Cytogenetics Market, valued at USD 2.24 Billion in 2024, is projected to grow to USD 3.62 Billion by 2030, exhibiting a CAGR of 8.33%. This growth is primarily driven by the increasing prevalence of genetic conditions and oncological diseases, alongside the rising demand for personalized medicine. Key challenges include the high cost of instrumentation and the need for specialized expertise, while key trends involve the integration of AI and automation to enhance efficiency and precision in workflows.

**5. Muscles, the New Flex: Abbott Launches Two New Ensure Max Protein Shakes to Tap into Growing Muscle Health Movement**
- Source: Finviz | 20251204T110000 | Bullish | Relevance: 98%
- Abbott (NYSE: ABT) has launched two new Ensure Max Protein shakes, Ensure Max Protein 42g and Ensure Max Protein 2 in 1 Muscle Support, to address muscle health, particularly for adults over 40 who can lose significant muscle mass. Former NFL MVP Matt Ryan is partnering with Abbott to raise awareness about the importance of muscle health. The products are designed for active adults and older adults, with the latter containing CaHMB to help slow muscle breakdown, and are exclusively available at Walmart until March 2026.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | BTIG | $145 | $145 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($0.12M) |
| Sells | 1 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 22.0x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $211.0B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 22.0 |
| Current P/E | 24.3 |
| YoY Growth | 10.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -2.1% to -3.2% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.2pp (needs >3.0% for momentum thesis). Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 42.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.20% (CS: 20) | Weak |
| RSI_14 | 42.1 | Neutral |
| MACD Histogram | -0.20 | Bearish |
| vs SMA20 | 0.981x | Below |
| vs SMA50 | 0.972x | Below |
| vs SMA200 | 0.956x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $125.08
- **Stop Loss:** $120.12 (4.0% risk)
- **Target:** $130.04 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 100
- **Position Value:** $12,508.00
- **Portfolio %:** 12.51%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*